An Ethical Argument for Ending Human Trials of Amyloid-Lowering Therapies in Alzheimer’s Disease

American Journal of Bioethics Neuroscience 15 (2):80-81 (2024)
  Copy   BIBTEX

Abstract

Given the past two decades of over 40 failed trials of amyloid-lowering therapies in Alzheimer’s Disease (AD), many of which succeeded in lowering amyloid as designed, we present an ethical argument for emptying the drug pipeline of tests of amyloid-lowering agents so as to end the historical dominance of the amyloid-reducing therapeutic approach in AD.

Other Versions

No versions found

Links

PhilArchive

    This entry is not archived by us. If you are the author and have permission from the publisher, we recommend that you archive it. Many publishers automatically grant permission to authors to archive pre-prints. By uploading a copy of your work, you will enable us to better index it, making it easier to find.

    Upload a copy of this work     Papers currently archived: 103,945

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

Alzheimer's disease untangled.Fiona Crawford & Alison Goate - 1992 - Bioessays 14 (11):727-734.

Analytics

Added to PP
2022-10-07

Downloads
40 (#614,025)

6 months
7 (#590,730)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

Dementia Prevention Guidelines Should Explicitly Mention Deprivation.Timothy Daly - 2024 - American Journal of Bioethics Neuroscience 15 (1):73-76.

Add more citations